Clinical trials
Mutation clinical trials
Below are recruiting mutation clinical trials, each written for real people, not researchers. We’re tracking 714 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04090567RecruitingPhase 2
Olaparib with two partners for advanced BRCA breast cancer
This trial tests whether the drug olaparib works better when combined with cediranib or AZD6738 in people with advanced or metastatic BRCA (inherited) breast cancer. It may help shrink tumors or slow cancer growth after prior treatment with a PARP inhibitor.
Houston, TexasAges 18 years+ - NCT03702309Recruiting
Banking and testing blood samples to study cancer
This study collects blood samples to “test and store” (bank) information that may help doctors understand cancer in the future. You might be able to join if you’re an adult with confirmed cancer or a higher-than-usual risk for cancer.
Toronto, OntarioAges 18 years+ - NCT07686445RecruitingPhase 1
Study of AN4035 for advanced cancers with RAS mutations
This trial tests a new drug, AN4035, for people with advanced cancers that have a RAS mutation and high levels of a protein called CEACAM5. The drug may help shrink tumors or slow their growth.
PerthAges 18 years+ - NCT06008392Recruiting
Mayo Clinic cancer genetics research study
This study collects blood, saliva, tumor tissue, or hair samples to look for inherited and tumor-related gene changes that may explain your cancer, guide prevention, or help find better treatments. You can join if you are a Mayo Clinic patient with cancer and your doctor has ordered genetic testing.
Scottsdale, ArizonaAges 18 years+ - NCT07020221RecruitingPhase 1/Phase 2
Study of VS-7375 for cancers with a KRAS G12D mutation
This study tests an experimental drug called VS-7375 for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug can shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT05033691Recruiting
Osimertinib plus early brain radiation versus osimertinib alone
This trial tests whether starting focused radiation to brain spots early (called SRS) along with osimertinib works better than taking osimertinib alone. It is for people with lung cancer that has an EGFR mutation and has not yet caused major brain symptoms.
JerusalemAges 18–120 - NCT05503667RecruitingPhase 2
Testing EGFR drugs before lung surgery in certain stage III cancers
This trial tests whether taking furmonertinib alone, or furmonertinib plus bevacizumab, before surgery can improve outcomes for people with EGFR-mutated lung adenocarcinoma that has not spread to distant organs. It may help shrink the tumor and make surgery more effective.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT04095195Recruiting
Pancreatic cancer risk registry for high-risk families
This study builds a registry of people with a higher-than-average risk of pancreatic cancer, based on family history or inherited gene conditions. If you join the extra imaging follow-up, it helps your care team monitor risk earlier.
Rozzano, MilanAges 18–80 - NCT05761470RecruitingPhase 2
Test before-surgery cancer treatment for breast tumors with DNA repair gene changes
This trial tests a combination of medications given before surgery (neoadjuvant therapy) for early breast cancer. It is designed for tumors with certain “DNA repair” gene mutations and aims to improve treatment results while shrinking or controlling the cancer.
Guangzhou, GuangdongAges 18–75 - NCT05768490RecruitingPhase 3
Radiation plus targeted pills for EGFR lung cancer brain spots
This Phase 3 study tests whether giving brain radiation early or later, along with almonertinib (a targeted pill), works better for people with EGFR-mutated non-small cell lung cancer that has a small number of brain metastases. It aims to control brain disease while checking safety and effectiveness in a carefully selected group.
Guangdong, GuangzhouAges 18–75 - NCT05858983RecruitingPhase 1/Phase 2
Gene therapy for certain RPE65 inherited eye conditions
This early-stage trial tests a gene therapy aimed at treating inherited retinal dystrophy caused by changes in the RPE65 gene on both copies. It may help slow vision loss or improve eye function, but the study is mainly about safety and learning how the treatment works.
Beijing, Beijing MunicipalityAges 8–45 - NCT06041776RecruitingPhase 3
Befotertinib after surgery for early-stage lung cancer with EGFR mutation
This trial tests if a targeted therapy pill (befotertinib) can lower the chance of cancer coming back after surgery for non-small cell lung cancer that has a specific EGFR mutation. You may be eligible if your tumor was completely removed and you have stage IB to IIIB disease.
BeijingAges 18 years+ - NCT06102928Recruiting
Anlotinib plus Aumolertinib for first-line treatment of advanced EGFR-mutant lung cancer
This trial tests a combination of two targeted drugs (anlotinib and aumolertinib) as the first treatment for advanced lung cancer with a specific EGFR mutation (L858R). The goal is to see if the combination works better than standard care.
Kunming, YunnanAges 18 years+ - NCT06088030RecruitingPhase 2
Arsenic trioxide plus chemo for p53-mutated childhood cancer
This trial tests if adding arsenic trioxide to standard chemotherapy can help children with cancers that have a certain p53 gene change. The goal is to see if the drug can reactivate the broken p53 protein to fight the tumor.
Guangzhou, GuangdongAges Up to 18 years - NCT06192849RecruitingPhase 2
Furmonertinib after surgery for EGFR 20 insertion lung cancer
This trial tests a targeted pill (furmonertinib) to prevent your lung cancer from coming back after surgery. It is for people with a certain genetic change in their tumor (EGFR exon 20 insertion) and stage IB, II, or IIIA disease.
Chengdu, SichuanAges 18 years+ - NCT06218810RecruitingPhase 2
Combination therapy for advanced MSS, RAS-mutated colorectal cancer
This trial tests a new combination of three medicines for people with a certain type of advanced colorectal cancer that has not been treated before. It aims to see if adding an immunotherapy drug (Cadonilimab) to standard chemotherapy and a targeted therapy (Bevacizumab) can help shrink tumors and delay disease progression.
ShanghaiAges 18–75 - NCT07128199RecruitingPhase 3
Zipalertinib after surgery for early-stage lung cancer with uncommon EGFR mutations
This study tests whether taking zipalertinib after lung cancer surgery can help prevent the cancer from coming back in people whose tumors have uncommon EGFR gene changes. It is a pill taken daily after recovery from surgery.
Anchorage, AlaskaAges 18 years+ - NCT06277466Recruiting
Gene changes and diabetes risk study
This study looks at how certain gene changes affect blood sugar control in type 2 diabetes and also in people who have had pancreas surgery. It compares these groups with healthy volunteers to see how genes influence the risk of diabetes.
XuzhouAges 25–70 - NCT06053099Recruiting
Study of osimertinib after surgery for EGFR-mutated lung cancer
This trial collects data from people with early-stage lung cancer that has a common EGFR mutation. After complete surgical removal of the tumor, participants take osimertinib for 3 years and are followed regularly to see how well the treatment works and why resistance might develop.
AngersAges 18 years+ - NCT06363734RecruitingPhase 2
Targeted drug combo for EGFR-mutant lung cancer after resistance
This trial tests a combination of two targeted drugs (osimertinib and dalpiciclib) for people with advanced lung cancer whose tumors have a specific EGFR mutation and a change in the CDK4/6 pathway, and whose cancer has stopped responding to a third-generation EGFR targeted therapy. The goal is to see if this combination can help shrink tumors or slow cancer growth.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT06413992RecruitingPhase 2
Camrelizumab plus fluzoparib for TP53-mutated endometrial cancer
This trial tests a combination of two drugs, camrelizumab (an immunotherapy) and fluzoparib (a PARP inhibitor), for people with a specific type of endometrial cancer that has a TP53 gene mutation. It may offer a new option for advanced or recurrent disease after limited prior treatment.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06548919Recruiting
Treatment patterns for ESR1-mutated advanced breast cancer
This study looks at how Chinese patients with a specific gene change (ESR1 mutation) in ER-positive, HER2-negative advanced breast cancer are currently being treated. It will help doctors understand what treatments work best for people whose cancer has stopped responding to hormone therapy.
Suzhou, JiangsuAges 18 years+ - NCT06316960RecruitingPhase 2
Avapritinib for children with relapsed or resistant CBF-AML and KIT mutation
This trial tests a targeted drug called avapritinib in children and teens with a specific type of leukemia (CBF-AML) that has a KIT gene change and has come back or not responded to treatment. The goal is to see if avapritinib is safe and effective for these patients.
Hefei, AnhuiAges Up to 18 years - NCT06348927RecruitingPhase 2
Sunvozertinib plus anlotinib for first-line EGFR-mutant lung cancer
This trial tests a combination of two oral drugs (sunvozertinib and anlotinib) as a first treatment for advanced lung cancer with certain EGFR mutations plus other gene changes. It aims to see if this combination works better than standard treatments.
Changsha, HunanAges 18 years+
Hear when a new Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for mutation?
- Yes. Clin2 currently lists 714 recruiting mutation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a mutation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a mutation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.